fenofibrate has been researched along with endothelin-1 in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (58.82) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, KJ; Gu, ZL; Guo, CY; Xie, ML; Zhou, WX | 1 |
| Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Lavoie, MF; Schiffrin, EL; Touyz, RM | 1 |
| Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC | 1 |
| Goto, K; Iemitsu, M; Irukayama-Tomobe, Y; Kasuya, Y; Miyauchi, T; Ogata, T; Sakai, S; Sudo, T; Takanashi, M; Yamaguchi, I | 1 |
| Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Takanashi, M; Yamaguchi, I | 1 |
| Goto, K; Irukayama-Tomobe, Y; Kasuya, Y; Miyauchi, T; Sakai, S; Yamaguchi, I | 1 |
| Brigadeau, F; Duriez, P; Fruchart, JC; Gelé, P; Lacroix, D; Marquié, C; Martin-Nizard, F; Staels, B; Torpier, G; Wibaux, M | 1 |
| Gao, J; Le, K; Li, R; Liu, P; Pi, R; Wang, P; Zhang, H; Zheng, W | 1 |
| Antonini, R; Antonini, TM; Arca, M; Fraioli, A; Letizia, C; Luigi, P; Maddaloni, M; Mastrantoni, M; Montali, A; Pigna, G | 1 |
| Adeghate, E; Kalasz, H; Teke, K; Veress, G | 1 |
| Anderson, HD; Huang, Y; Kopilas, MA; Netticadan, T; O'Hara, KA; Shao, Z; Yu, L; Zhang, H | 1 |
| Bao, Y; Cai, Y; Huang, H; Lan, T; Le, K; Li, C; Li, R; Liu, P; Moss, J; Shen, X; Wu, X; Xu, S; Zou, J | 1 |
| Chew, GT; Glineur, C; Gross, B; Lamas, S; Martin-Nizard, F; Neve, B; Rodríguez-Pascual, F; Rommens, C; Staels, B; Watts, GF | 1 |
| Gonsalves, CS; Kalra, VK; Li, C; Malik, P; Tahara, SM | 1 |
| Chen, JW; Jen, HL; Lin, SJ; Yin, WH | 1 |
| Chen, JW; Chen, YH; Jen, HL; Lin, SJ; Liu, PL; Yin, WH | 1 |
1 review(s) available for fenofibrate and endothelin-1
| Article | Year |
|---|---|
Medicinal chemistry of drugs used in diabetic cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Calcium Channel Blockers; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus; Endothelin-1; Fenofibrate; Humans; Hypoglycemic Agents; Peroxisome Proliferator-Activated Receptors; Receptors, Angiotensin | 2010 |
2 trial(s) available for fenofibrate and endothelin-1
| Article | Year |
|---|---|
Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Biomarkers; Endothelin-1; Endothelium, Vascular; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles | 2007 |
Fenofibrate inhibits endothelin-1 expression by peroxisome proliferator-activated receptor α-dependent and independent mechanisms in human endothelial cells.
Topics: Apoptosis Regulatory Proteins; Binding Sites; Brachial Artery; Cell Cycle Proteins; Cell Line; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Down-Regulation; Dyslipidemias; Endothelial Cells; Endothelin-1; Fenofibrate; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Hypolipidemic Agents; Phosphorylation; PPAR alpha; Promoter Regions, Genetic; Repressor Proteins; Signal Transduction; Time Factors; Transcription, Genetic; Transfection; Transforming Growth Factor beta; Vasodilation | 2013 |
14 other study(ies) available for fenofibrate and endothelin-1
| Article | Year |
|---|---|
Effect of lipanthyl on mRNA expression of endothelin-1 and nitric-oxide synthase in atherosclerotic vessel wall in rabbits.
Topics: Animals; Aorta, Abdominal; Arteriosclerosis; Endothelin-1; Fenofibrate; Hypolipidemic Agents; Male; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Rabbits; Random Allocation; RNA, Messenger | 2000 |
Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts.
Topics: Animals; Cardiomegaly; Collagen Type I; Collagen Type III; Endomyocardial Fibrosis; Endothelin-1; Fenofibrate; Male; Models, Animal; Myocardium; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Transcription Factors | 2002 |
Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Endothelin-1; Endothelins; Extracellular Matrix; Fenofibrate; Hypertension; In Vitro Techniques; Male; Mesenteric Arteries; Oxygen; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tunica Media; Vascular Resistance; Vasodilator Agents | 2003 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; Endothelins; Fenofibrate; Fibrosis; Heart; Heart Ventricles; Hypertension; Myocardium; Protein Precursors; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Ventricular Remodeling | 2003 |
Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.
Topics: Animals; Animals, Newborn; Aorta; Cells, Cultured; Disease Models, Animal; Endothelin-1; Fenofibrate; Genes, fos; Genes, jun; Hypertrophy, Left Ventricular; JNK Mitogen-Activated Protein Kinases; Ligation; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Myocytes, Cardiac; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Signal Transduction; Tetradecanoylphorbol Acetate; Transcription Factor AP-1; Transcription Factors | 2004 |
The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation.
Topics: Animals; Animals, Newborn; Cell Proliferation; Cells, Cultured; DNA Replication; Down-Regulation; Endothelin-1; Fenofibrate; Fibroblasts; Heart Ventricles; Hypolipidemic Agents; PPAR alpha; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2004 |
Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes.
Topics: Animals; Animals, Newborn; Cell Size; Cells, Cultured; Endothelin-1; Fenofibrate; Hypertrophy; Myocytes, Cardiac; p38 Mitogen-Activated Protein Kinases; Phosphorylation; PPAR alpha; Rats; Rats, Sprague-Dawley; Signal Transduction; Time Factors | 2004 |
The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.
Topics: Acyl-CoA Oxidase; Animals; Atrial Natriuretic Factor; Biomarkers; Cardiac Output, Low; Cardiomyopathies; Carnitine O-Palmitoyltransferase; Endothelin-1; Female; Fenofibrate; Myocardium; Natriuretic Peptide, Brain; Oxidative Stress; PPAR alpha; RNA, Messenger; Swine; Tachycardia; Thiobarbituric Acid Reactive Substances; Ventricular Dysfunction, Left | 2007 |
Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Nucleus; Cells, Cultured; Endothelin-1; Fenofibrate; Gene Expression Regulation; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Myocytes, Cardiac; Nerve Tissue Proteins; NFATC Transcription Factors; Phosphorylation; PPAR alpha; Protein Transport; Rats; Rats, Sprague-Dawley; Transfection | 2007 |
Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.
Topics: Age Factors; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Chromans; Diacylglycerol Kinase; Endothelin-1; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Myocytes, Cardiac; Peroxisome Proliferator-Activated Receptors; Rats; Rats, Sprague-Dawley; Signal Transduction; Thiazolidinediones; Troglitazone; Up-Regulation | 2011 |
PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4.
Topics: Animals; Cardiomegaly; Cell Nucleus; Dose-Response Relationship, Drug; Endothelin-1; Fenofibrate; GATA4 Transcription Factor; Gene Expression Regulation; Myocytes, Cardiac; Natriuretic Peptide, Brain; NFATC Transcription Factors; PPAR alpha; Promoter Regions, Genetic; Protein Binding; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2012 |
Peroxisome proliferator-activated receptor-α-mediated transcription of miR-301a and miR-454 and their host gene SKA2 regulates endothelin-1 and PAI-1 expression in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Cell Line; Chromosomal Proteins, Non-Histone; Endothelin-1; Fenofibrate; Gene Expression Regulation; Humans; Hypertension, Pulmonary; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; MicroRNAs; Placenta Growth Factor; Plasminogen Activator Inhibitor 1; PPAR alpha; Pregnancy Proteins; Promoter Regions, Genetic | 2015 |
Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin.
Topics: Adiponectin; Animals; Animals, Newborn; Cardiomegaly; Endothelin-1; Fenofibrate; Humans; Hypolipidemic Agents; Male; Myocytes, Cardiac; Phosphorylation; PPAR alpha; Rats; Rats, Sprague-Dawley | 2017 |
Peroxisome Proliferator-Activated Receptor
Topics: Adiponectin; Blotting, Western; Cells, Cultured; Electrophoretic Mobility Shift Assay; Endothelin-1; Fenofibrate; Fluorescent Antibody Technique; Humans; Hypertrophy; Immunoprecipitation; Myocytes, Cardiac; NF-kappa B; PPAR alpha | 2016 |